Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 8,600 shares, a growth of 230.8% from the December 31st total of 2,600 shares. Based on an average daily trading volume, of 362,400 shares, the days-to-cover ratio is currently 0.0 days.

Oncotelic Therapeutics Stock Up 2.9 %

Shares of OTCMKTS OTLC traded up $0.00 during mid-day trading on Wednesday, reaching $0.03. 1,500 shares of the company’s stock traded hands, compared to its average volume of 181,029. Oncotelic Therapeutics has a 1-year low of $0.02 and a 1-year high of $0.05. The stock has a market cap of $11.38 million, a P/E ratio of -2.80 and a beta of -0.27. The business has a 50-day simple moving average of $0.03 and a 200 day simple moving average of $0.03. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.01 and a quick ratio of 0.01.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.